90 related articles for article (PubMed ID: 15591712)
21. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
22. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
23. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
26. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
27. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
29. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
30. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
31. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
32. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood JM; Gonzalez R; Reintgen D; Clingan PR; McWilliams RR; de Alwis DP; Zimmermann A; Brown MP; Ilaria RL; Millward MJ
Cancer; 2011 Oct; 117(20):4732-9. PubMed ID: 21456002
[TBL] [Abstract][Full Text] [Related]
34. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma.
Smylie MG; Wong R; Mihalcioiu C; Lee C; Pouliot JF
Invest New Drugs; 2007 Apr; 25(2):155-9. PubMed ID: 16957835
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Caraglia M; Addeo R; Costanzo R; Montella L; Faiola V; Marra M; Abbruzzese A; Palmieri G; Budillon A; Grillone F; Venuta S; Tagliaferri P; Del Prete S
Cancer Chemother Pharmacol; 2006 Jan; 57(1):34-9. PubMed ID: 16010592
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology.
Assaf C; Becker JC; Beyer M; Cozzio A; Dippel E; Klemke CD; Kurschat P; Weichenthal M; Stadler R
J Dtsch Dermatol Ges; 2013 Apr; 11(4):338-47. PubMed ID: 23279629
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment.
Vorobiof DA; Rapoport BL; Mahomed R; Karime M
Melanoma Res; 2003 Apr; 13(2):201-3. PubMed ID: 12690306
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns and outcomes in patients with advanced melanoma in France.
Bedane C; Leccia MT; Sassolas B; Bregman B; Lebbé C;
Curr Med Res Opin; 2013 Oct; 29(10):1297-305. PubMed ID: 23808961
[TBL] [Abstract][Full Text] [Related]
39. Response of progressive fibromatosis to therapy with liposomal doxorubicin.
Wehl G; Rossler J; Otten JE; Boehm N; Uhl M; Kontny U; Niemeyer C
Onkologie; 2004 Dec; 27(6):552-6. PubMed ID: 15591714
[TBL] [Abstract][Full Text] [Related]
40. Caelyx in malignant mesothelioma: a phase II EORTC study.
Baas P; van Meerbeeck J; Groen H; Schouwink H; Burgers S; Daamen S; Giaccone G
Ann Oncol; 2000 Jun; 11(6):697-700. PubMed ID: 10942058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
